Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095866 | 0.77 | CYP1A2 (0.35) | ALDH1A1KMT2ACYP1A2CYP2A6DOT1L | |
| SCHEMBL11656389 | 0.74 | TSHR (0.39) | ALDH1A1KMT2AKDM4ECYP1A2CYP2A6 | |
| SCHEMBL16746561 | 0.72 | CYP1A2 (0.43) | ALDH1A1KMT2AKDM4ECYP1A2CYP2A6 | |
| SCHEMBL11048901 | 0.70 | KMT2A (0.47) | ALDH1A1KMT2AKDM4EL3MBTL1LMNA | |
| SCHEMBL14382392 | 0.69 | AOC3 (0.42) | ALDH1A1CYP1A2CYP2A6DOT1LLMNA | |
| SCHEMBL21111149 | 0.68 | CYP1A2 (0.35) | ALDH1A1KMT2ACYP1A2CYP2A6DOT1L | |
| Acetonitrile SCHEMBL27536435 | 0.65 | TSHR (0.46) | ALDH1A1CYP1A2CYP2A6PSMB8LMNA | |
| SCHEMBL11508215 | 0.65 | ALDH1A1 (0.36) | ALDH1A1KDM4EL3MBTL1LMNATSHR | |
| SCHEMBL3787606 | 0.65 | MAPT (0.44) | ALDH1A1KMT2AKDM4EL3MBTL1CYP1A2 | |
| SCHEMBL19111974 | 0.65 | TAAR1 (0.38) | KDM4ECYP1A2CYP2A6DOT1LLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067614-B2 | N-substituted (benzoimidazol-2-yl)phenylamines, processes for their preparation, their use as a medicament or diagnostic aid, and a medicament comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20100168196-A1 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-01 | — | — | US | disclosed |
| EP-1857445-B1 | Substituted 2 amino imidazoles, method for their manufacture and their use as a drug or diagnostic and drug containing them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-15 | — | — | EP | disclosed |
| US-20080275098-A1 | Inhibit sodium proton exchangers; central nervous system, respiratory system, cardiovascular, urogenital, pyschological, biliary function and kidney disorders; sleep apnea, strokes; ketalization, acetalization, cyclization; similar to clonidine; hypotensive, antidiabetic, and antiischemic agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275098-A1 | Inhibit sodium proton exchangers; central nervous system, respiratory system, cardiovascular, urogenital, pyschological, biliary function and kidney disorders; sleep apnea, strokes; ketalization, acetalization, cyclization; similar to clonidine; hypotensive, antidiabetic, and antiischemic agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275098-A1 | Inhibit sodium proton exchangers; central nervous system, respiratory system, cardiovascular, urogenital, pyschological, biliary function and kidney disorders; sleep apnea, strokes; ketalization, acetalization, cyclization; similar to clonidine; hypotensive, antidiabetic, and antiischemic agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| US-7442717-B2 | Substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| US-7442717-B2 | Substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| US-7442717-B2 | Substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| US-20080167359-A1 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| EP-1592671-B1 | N-SUBSTITUTED (BENZOIMIDAZOLE-2-YL) PHENYL AMINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT AND MEDICAMENT CONTAINING SAID SUBSTANCES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-04-09 | — | — | EP | disclosed |
| EP-1857445-A2 | Substituted 2 amino imidazoles, method for their manufacture and their use as a drug or diagnostic and drug containing them | Sanofi-Aventis Deutschland GmbH (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1592669-B1 | SUBSTITUTED 2-AMINOIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR AS A DIAGNOSTIC REAGENT, AND MEDICAMENT CONTAINING THESE COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1592669-B1 | SUBSTITUTED 2-AMINOIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR AS A DIAGNOSTIC REAGENT, AND MEDICAMENT CONTAINING THESE COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1592669-A2 | NOVEL SUBSTITUTED 2-AMINOIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR AS A DIAGNOSTIC REAGENT, AND MEDICAMENT CONTAINING THESE COMPOUNDS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-09 | — | — | EP | disclosed |
| US-20050054705-A1 | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20040259927-A1 | Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-23 | — | — | US | disclosed |
| WO-2004069806-A2 | SUBSTITUTED 2-AMINOIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR AS A DIAGNOSTIC REAGENT, AND MEDICAMENT CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259927-A1 | Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid | NDUFAB1, ABAT, NDUFAF1 | ALDH1A1 231/4885KMT2A 1388/4885KDM4E 2643/4885 |
| US-20080167359-A1 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them | SLC10A1, SLC9A3, ABCB11 | ALDH1A1 1564/4885KMT2A 2265/4885KDM4E 3412/4885 |
| US-20080275098-A1 | Inhibit sodium proton exchangers; central nervous system, respiratory system, cardiovascular, urogenital, pyschological, biliary function and kidney disorders; sleep apnea, strokes; ketalization, acetalization, cyclization; similar to clonidine; hypotensive, antidiabetic, and antiischemic agents | ATP6V1B1, SLC10A1, GLS | ALDH1A1 831/4885KMT2A 629/4885KDM4E 1280/4885 |
| US-20100168196-A1 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them | SLC10A1, SLC9A3, ABCB11 | ALDH1A1 1564/4885KMT2A 2265/4885KDM4E 3412/4885 |
| US-20050054705-A1 | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | SLC10A1, SLC9A3, NHERF1 | ALDH1A1 1528/4885KMT2A 2220/4885KDM4E 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.